Laboratories

Print

Genome Research

Update : 2017-05-10

Overview

Our laboratory has started research activities since January 2005, aiming to study the effectiveness of molecular cancer therapeutics at the genome level. Our goals are to identify new molecular targets for tumor-selective therapy and to develop diagnosis methods for predicting drug responsiveness in cancer patients. For the attainment of the purpose, we promote two projects, using genome technologies: 1) basic research for microenvironment-oriented, molecular-targeted therapy and 2) translational research for diagnosis of drug responsiveness in molecular-targeted therapy.

Projects

  1. Basic research for microenvironment-oriented, molecular-targeted therapy
  2. Translational research for diagnosis of drug responsiveness in molecular-targeted therapy

Publications

Publications

Koido M, Haga N, Furuno A, Tsukahara S, Sakurai J, Tani Y, Sato S, Tomida A.
Mitochondrial deficiency impairs hypoxic induction of HIF-1 transcriptional activity and retards tumor growth.
Oncotarget, in press (2017)
Nagasawa I, Kunimasa K, Tsukahara S, Tomida A.
BRAF-mutated cells activate GCN2-mediated integrated stress response as a cytoprotective mechanism in response to vemurafenib.
Biochem Biophys Res Commun, 482, 1491-1497 (2017)
Mashima, T., Ushijima, M., Matsuura, M., Tsukahara, S., Kunimasa, K., Furuno, A., Saito, S., Kitamura, M., Soma-Nagae, T., Seimiya, H., Dan, S., Yamori, T., Tomida, A.
Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation.
Cancer Sci, 106, 909-920 (2015)
Tsukumo, Y., Tsukahara, S., Furuno, A., Iemura, S., Natsume, T., Tomida, A.
TBL2 is a novel PERK-binding protein that modulates stress-signaling and cell survival during endoplasmic reticulum stress.
PLoS One, 9, e112761 (2014)
Matsuo, J., Tsukumo, Y., Saito, S., Tsukahara, S., Sakurai, J., Sato, S., Kondo, H., Ushijima, M., Matsuura, M., Watanabe, T., Tomida, A.
Hyperactivation of 4E-binding protein 1 as a mediator of biguanide-induced cytotoxicity during glucose deprivation.
Mol Cancer Ther, 11, 1082-1091 (2012)

Contact

Akihiro Tomida, Ph.D. (Chief)
3-8-31, Ariake, Koto-ku, Tokyo135-8550, Japan
TelF+81-3-3570-0514@FaxF+81-3-3570-0484
E-mail: akihiro.tomida@jfcr.or.jp

Return to Top of Page